drugset / Trial / NCT00373516

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

NCT00373516 ↗

Phase 2 Completed 150 enrolled QuatRx Pharmaceuticals Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks

Timeline

Start
2004-09
Primary completion
—
Completion
2005-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Becocalcidiol Small molecule 75 unknown Topical

Indications